Ref ID: 15138
Author:
A. LEPAK, H. SANCHEZ, K. MARCHILLO,D. R. ANDES;
Author address:
Univ. of Wisconsin, Madison, WI.
Full conference title:
50th Annual ICAAC
Date: 12 September 2014
Abstract:
Background:Aspergillosis is a devastating cause of infection in immunocompromised hosts. Despite therapeutic advances outcomes remain poor. PD approaches have been useful for design of optimal dosing strategies for many infections but is underexplored for aspergillosis. We compared the PD target for two commonly utilized antifungal drug classes using a persistently neutropenic and corticosteroid suppressed murine IPA model.Methods:In vitro testing revealed a posaconazole (P) MIC and caspofungin (C) MEC of 0.5 ug/ml. Mice had 0.15 ng/ml of lungA. fumigatus293 DNA when a 7 d regimen of either P (0.625-160 mg/kg/d) or C (0.3125-80 mg/kg/d) were started. A sigmoid Emax model was used to estimate doses and AUC/MIC or MEC needed to achieve a variety of treatment endpoints based upon the quantity of lungAspergillusat the end of therapy (static dose [SD], 1 log reduction [1log], ED25, 50, and 75). Mann-Whitney test was used to compare the PD targets for P and C.Results:The lung burden ofAspergillusincreased nearly 2 log10 in control mice. The exposure response relationships were well described using the Emax model (R2=0.63-0.84). The maximal reduction in burden was greater (p=0.007) for P (2.4±0.29log10) than C (1.7±0.46 log10). For each treatment endpoint, C required more drug whether expressed on a mg/kg or AUC/MIC or MEC basis (2.8- to 36-fold, p=0.03). ED50 was similar to the SD and ED75 was similar to 1log endpoint. Total drug AUC/MIC or MEC relationships were similar.
Conclusion:The Emax model is useful to characterize the PD relationship for these antifungals using a quantitativeAspergillusDNA endpoint. The PD target was markedly different for the triazole and echinocandin in this model.
Abstract Number: A1-040
Conference Year: 2010
Link to conference website: NULL
New link:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a